What are the cardiovascular benefits of using incretin analogues in Peripheral Artery Disease?
Peripheral artery disease (PAD) is a condition where narrowed arteries reduce blood flow to the limbs, often causing leg pain while walking. People with PAD have a high risk of heart attack and stroke. Incretin analogues, such as GLP-1 receptor agonists, are medications originally used for diabetes and weight loss. Research shows they also provide significant cardiovascular benefits for people with PAD, including improved walking ability and fewer major cardiovascular events.
What the research says
A 2025 state-of-the-art review specifically examined the cardiovascular evidence for incretin analogues across multiple clinical scenarios, including symptomatic peripheral artery disease 2. The review notes that GLP-1 receptor agonists provide cardiovascular benefits through direct effects on blood vessel lining, reduced inflammation in immune cells, and decreased fat around the heart, as well as indirect benefits from weight loss, better blood sugar control, and lower blood pressure 2.
In people with PAD, these medications have been shown to improve walking distance and reduce the risk of major adverse limb events 2. Additionally, a meta-analysis of heart failure trials found that GLP-1 receptor agonists significantly reduced heart failure worsening events in patients with preserved ejection fraction (a type of heart failure common in PAD) 6. This is important because PAD and heart failure often occur together.
The broader cardiometabolic benefits of incretin analogues are supported by evidence showing they reduce cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, which includes PAD 23. A unified cardiometabolic disease framework links PAD with other conditions like diabetes, heart disease, and kidney disease through shared mechanisms such as inflammation and insulin resistance 3. Incretin analogues target these shared pathways, offering benefits across multiple organ systems 13.
What to ask your doctor
- Could a GLP-1 receptor agonist help improve my walking distance or leg symptoms from PAD?
- What are the potential cardiovascular benefits of incretin analogues for someone with my specific health profile?
- Are there any risks or side effects I should consider before starting this type of medication?
- How would this medication fit with my current treatments for PAD, such as antiplatelet therapy or statins?
- Should I see a cardiologist or vascular specialist to discuss starting a GLP-1 receptor agonist?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.